Evaluation of MHC class I peptide binding prediction servers: Applications for vaccine research
暂无分享,去创建一个
[1] D. Cox,et al. An Analysis of Transformations , 1964 .
[2] J A Swets,et al. Measuring the accuracy of diagnostic systems. , 1988, Science.
[3] H. Rammensee,et al. Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast , 1991, The Journal of experimental medicine.
[4] H. Rammensee,et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.
[5] J. Coligan,et al. Presentation of three different viral peptides, HTLV-1 Tax, HCMV gB, and influenza virus M1, is determined by common structural features of the HLA-A2.1 molecule. , 1992, Journal of immunology.
[6] D. Wiley,et al. The antigenic identity of peptide-MHC complexes: A comparison of the conformations of five viral peptides presented by HLA-A2 , 1993, Cell.
[7] J. Berzofsky,et al. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans , 1994, Journal of virology.
[8] K. Parker,et al. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.
[9] S. Stacey,et al. Human cytotoxic T lymphocytes stimulated by endogenously processed human papillomavirus type 11 E7 recognize a peptide containing a HLA-A2 (A*0201) motif. , 1994, Immunology.
[10] S. Burrows,et al. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. , 1994, The Journal of general virology.
[11] Don C. Wiley,et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide , 1994, Nature.
[12] A. Samri,et al. CTLs from lymphoid organs recognize an optimal HLA-A2-restricted and HLA-B52-restricted nonapeptide and several epitopes in the C-terminal region of HIV-1 Nef. , 1995, Journal of immunology.
[13] F. Chisari,et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. , 1995, The Journal of clinical investigation.
[14] H. Rammensee,et al. Chemistry of peptides associated with MHC class I and class II molecules. , 1995, Current opinion in immunology.
[15] V. Engelhard,et al. Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice. , 1995, International immunology.
[16] J. Berzofsky,et al. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. , 1995, Journal of immunology.
[17] J. Berzofsky,et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules , 1995, Journal of virology.
[18] F. Marincola,et al. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35) , 1996, The Journal of experimental medicine.
[19] R P Johnson,et al. Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes , 1996, Journal of virology.
[20] L. Fugger,et al. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[21] B. Walker,et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. , 1996, Journal of immunology.
[22] A. Rickinson,et al. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. , 1997, Journal of immunology.
[23] A. Sette,et al. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. , 1997, Cancer research.
[24] A. Kumar,et al. Immediate Early and Early Lytic Cycle Proteins Are Frequent Targets of the Epstein-Barr Virus–induced Cytotoxic T Cell Response , 1997, The Journal of experimental medicine.
[25] R. Khanna,et al. Identification of a Cytotoxic T-Lymphocyte Response to the Novel BARF0 Protein of Epstein-Barr Virus: a Critical Role for Antigen Expression , 1998, Journal of Virology.
[26] S. Burrows,et al. Identification of cytotoxic T cell epitopes within Epstein‐Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype‐restricted immune recognition of EBV‐infected cells by LMP1‐specific cytotoxic T lymphocytes , 1998, European journal of immunology.
[27] S. Burrows,et al. EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design. , 1999, Journal of Immunology.
[28] A Sette,et al. Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. , 1999, Journal of immunology.
[29] J A Madrigal,et al. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. , 1999, Journal of immunology.
[30] R. Offringa,et al. Differential binding of viral peptides to HLA‐A2 alleles. Implications for human papillomavirus type 16 E7 peptide‐based vaccination against cervical carcinoma , 1999, European journal of immunology.
[31] U. Şahin,et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.
[32] H. Rammensee,et al. SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.
[33] P R Kolatkar,et al. Knowledge-based grouping of modeled HLA peptide complexes. , 2000, Human immunology.
[34] Dominique Charron,et al. HLA-DR Restricted Peptide Candidates for Bee Venom Immunotherapy , 2000, The Journal of Immunology.
[35] O. Schueler‐Furman,et al. Structure‐based prediction of binding peptides to MHC class I molecules: Application to a broad range of MHC alleles , 2000, Protein science : a publication of the Protein Society.
[36] B. Bodey,et al. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. , 2000, Anticancer research.
[37] F. Lemonnier,et al. A general strategy to enhance immunogenicity of low‐affinity HLA‐A2.1‐associated peptides: implication in the identification of cryptic tumor epitopes , 2000, European journal of immunology.
[38] H. Grey,et al. Epitope affinity for MHC class I determines helper requirement for CTL priming , 2000, Nature Immunology.
[39] Maria V. Tejada-Simon,et al. Naturally Processed HLA Class II Peptides Reveal Highly Conserved Immunogenic Flanking Region Sequence Preferences That Reflect Antigen Processing Rather Than Peptide-MHC Interactions1 , 2001, The Journal of Immunology.
[40] Gajendra P. S. Raghava,et al. ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..
[41] Vladimir Brusic,et al. Computational immunology: The coming of age , 2002, Immunology and cell biology.
[42] P. Coulie,et al. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. , 2002, Cancer research.
[43] Forest M White,et al. Analysis of MHC Class II Antigen Processing by Quantitation of Peptides that Constitute Nested Sets , 2002, The Journal of Immunology.
[44] Thierry Boon,et al. Tumor‐specific shared antigenic peptides recognized by human T cells , 2002, Immunological reviews.
[45] Kun Yu,et al. Methods for Prediction of Peptide Binding to MHC Molecules: A Comparative Study , 2002, Molecular medicine.
[46] S. Rosenberg,et al. Identification of BING-4 Cancer Antigen Translated From an Alternative Open Reading Frame of a Gene in the Extended MHC Class II Region Using Lymphocytes From a Patient With a Durable Complete Regression Following Immunotherapy , 2002, The Journal of Immunology.
[47] D. Schadendorf,et al. Identification of known and novel immunogenic T‐cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL‐2‐based treatment , 2002, International journal of cancer.
[48] Hans-Georg Rammensee,et al. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[49] P. Moss,et al. Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. , 2002, The Journal of infectious diseases.
[50] E. Reinherz,et al. Prediction of MHC class I binding peptides using profile motifs. , 2002, Human immunology.
[51] M. Sathiamurthy,et al. Population of the HLA ligand database. , 2003, Tissue antigens.
[52] Gajendra P. S. Raghava,et al. ProPred1: Prediction of Promiscuous MHC Class-I Binding Sites , 2003, Bioinform..
[53] S Brunak,et al. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. , 2003, Tissue antigens.
[54] Daniel Gillet,et al. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells. , 2003, Cancer research.
[55] J. Muche,et al. Anti‐tumor immune responses and tumor regression induced with mimotopes of a tumor‐associated T cell epitope , 2003, European journal of immunology.
[56] J. Ehreth,et al. The value of vaccination: a global perspective. , 2003, Vaccine.
[57] S. Menzies,et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma , 2004, Cancer Immunology, Immunotherapy.
[58] Vladimir Brusic,et al. MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[59] P. Kloetzel,et al. MAPPP: MHC class I antigenic peptide processing prediction. , 2003, Applied bioinformatics.
[60] Ken Jung,et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[61] M. Kuroda,et al. Low Frequency of Cytotoxic T Lymphocytes against the Novel HLA-A*0201-Restricted JC Virus Epitope VP1p36 in Patients with Proven or Possible Progressive Multifocal Leukoencephalopathy , 2003, Journal of Virology.
[62] Bjoern Peters. Modeling the MHC-I pathway , 2003 .
[63] J. Shabanowitz,et al. The minor Histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein , 2003 .
[64] John Sidney,et al. Examining the independent binding assumption for binding of peptide epitopes to MHC-I molecules , 2003, Bioinform..
[65] O. Lund,et al. novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .
[66] Gajendra P. S. Raghava,et al. SVM based method for predicting HLA-DRB1*0401 binding peptides in an antigen sequence , 2004, Bioinform..
[67] Vladimir Brusic,et al. Computational methods for prediction of T-cell epitopes--a framework for modelling, testing, and applications. , 2004, Methods.
[68] H. Rammensee,et al. Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire , 2004, Cellular and Molecular Life Sciences CMLS.
[69] H. Rammensee,et al. Induction of Adipophilin-Specific Cytotoxic T Lymphocytes Using a Novel HLA-A2-Binding Peptide That Mediates Tumor Cell Lysis , 2004, Cancer Research.
[70] E. Bissonette,et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] Vladimir Brusic,et al. Pathogenic human thyroglobulin peptides in HLA-DR3 transgenic mouse model of autoimmune thyroiditis. , 2004, Cellular immunology.
[72] M. von Knebel Doeberitz,et al. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. , 2004, Cancer immunity.
[73] H. Yamana,et al. Phase I trial of patient‐oriented vaccination in HLA‐A2‐positive patients with metastatic hormone‐refractory prostate cancer , 2004, Cancer science.
[74] Søren Brunak,et al. Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach , 2004, Bioinform..
[75] Bjoern Peters,et al. HLA-A*0201, HLA-A*1101, and HLA-B*0702 transgenic mice recognize numerous poxvirus determinants from a wide variety of viral gene products. , 2005, The Journal of Immunology.
[76] Alessandro Sette,et al. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method , 2005, BMC Bioinformatics.
[77] Hyeoncheol Kim,et al. Prediction Rule Generation of MHC Class I Binding Peptides Using ANN and GA , 2005, ICNC.
[78] Vladimir Brusic,et al. MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides , 2005, Nucleic Acids Res..
[79] Steve Wilson,et al. The Immune Epitope Database and Analysis Resource: From Vision to Blueprint , 2005, PLoS biology.
[80] Francisco A. Chaves,et al. The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II:peptide complexes , 2005, Immunological reviews.
[81] Vladimir Brusic,et al. Information technologies for vaccine research , 2005, Expert review of vaccines.
[82] Bjoern Peters,et al. HLA-A*0201, HLA-A*1101, and HLA-B*0702 Transgenic Mice Recognize Numerous Poxvirus Determinants from a Wide Variety of Viral Gene Products1 , 2005, The Journal of Immunology.
[83] O. Lund,et al. An integrative approach to CTL epitope prediction: A combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions , 2005, European journal of immunology.
[84] Bjoern Peters,et al. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications , 2005, Immunogenetics.
[85] Gerd Ritter,et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[86] Lonce L. Wyse,et al. Deriving Matrix of Peptide-MHC Interactions in Diabetic Mouse by Genetic Algorithm , 2005, IDEAL.
[87] L. Tussey,et al. Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles. , 2005, Cancer immunity.
[88] Markus Weininger,et al. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin , 2006, Cancer Immunology, Immunotherapy.
[89] Jukka Partanen,et al. T Cell Epitope-Containing Peptides of the Major Dog Allergen Can f 1 as Candidates for Allergen Immunotherapy1 , 2005, The Journal of Immunology.
[90] Karina Yusim,et al. Immunoinformatics Comes of Age , 2006, PLoS Comput. Biol..
[91] Tin Wee Tan,et al. Structural bioinformatics Prediction of HLA-DQ 3 . 2 b Ligands : evidence of multiple registers in class II binding peptides , 2006 .
[92] Marij J P Welters,et al. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. , 2006, Advanced drug delivery reviews.
[93] Channa K. Hattotuwagama,et al. MHCPred 2.0 , 2006 .
[94] Z. Cao,et al. MHC-BPS: MHC-binder prediction server for identifying peptides of flexible lengths from sequence-derived physicochemical properties , 2006, Immunogenetics.
[95] Emil R Unanue,et al. The wide diversity and complexity of peptides bound to class II MHC molecules. , 2006, Current opinion in immunology.
[96] Shisong Jiang,et al. Overlapping synthetic peptides as vaccines , 2006, Vaccine.
[97] Chee Keong Kwoh,et al. Extreme Learning Machine for Predicting HLA-Peptide Binding , 2006, ISNN.
[98] Morten Nielsen,et al. A Community Resource Benchmarking Predictions of Peptide Binding to MHC-I Molecules , 2006, PLoS Comput. Biol..
[99] John Sidney,et al. Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients , 2006, AIDS.
[100] Fang-Xiang Wu,et al. Optimally-connected Hidden Markov Models for Predicting Mhc-binding Peptides , 2006, J. Bioinform. Comput. Biol..
[101] Darren R. Flower,et al. Predicting Class II MHC-Peptide binding: a kernel based approach using similarity scores , 2006, BMC Bioinformatics.
[102] Sylvie C. Fail,et al. The IMGT/HLA and IPD databases , 2006, Human mutation.
[103] Yoram Louzoun,et al. T-cell epitope repertoire as predicted from human and viral genomes. , 2006, Molecular immunology.
[104] Ora Schueler-Furman,et al. Learning MHC I - peptide binding , 2006, ISMB.
[105] Oliver Kohlbacher,et al. SVMHC: a server for prediction of MHC-binding peptides , 2006, Nucleic Acids Res..
[106] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[107] D. DeLuca,et al. A modular concept of HLA for comprehensive peptide binding prediction , 2006, Immunogenetics.
[108] V. Apostolopoulos,et al. Design of peptide-based vaccines for cancer. , 2006, Current medicinal chemistry.
[109] I. Svane,et al. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. , 2006, European urology.
[110] Thomas Lengauer,et al. DynaPred: A structure and sequence based method for the prediction of MHC class I binding peptide sequences and conformations , 2006, ISMB.
[111] Tomer Hertz,et al. PepDist: A New Framework for Protein-Peptide Binding Prediction based on Learning Peptide Distance Functions , 2006, BMC Bioinformatics.
[112] Channa K. Hattotuwagama,et al. MHCPred 2.0: an updated quantitative T-cell epitope prediction server. , 2006, Applied bioinformatics.
[113] Loris Nanni,et al. Machine learning algorithms for T-cell epitopes prediction , 2006, Neurocomputing.
[114] Marylène Lejeune,et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[115] J. Reimann,et al. Complexes of DNA vaccines with cationic, antigenic peptides are potent, polyvalent CD8(+) T-cell-stimulating immunogens. , 2006, Methods in Molecular Medicine.
[116] Ji Wan,et al. SVRMHC prediction server for MHC-binding peptides , 2006, BMC Bioinformatics.
[117] Steven G E Marsh,et al. The IMGT/HLA database. , 2007, Methods in molecular biology.
[118] N. Kallinteris,et al. Induction of potent CD4+ T cell‐mediated antitumor responses by a helper HER‐2/neu peptide linked to the Ii‐Key moiety of the invariant chain , 2007, International journal of cancer.
[119] I. Bozic,et al. Prediction of supertype-specific HLA class I binding peptides using support vector machines. , 2007, Journal of immunological methods.
[120] Anthony Kusalik,et al. Strength in numbers: achieving greater accuracy in MHC-I binding prediction by combining the results from multiple prediction tools , 2007, Immunome research.
[121] Bernard Maillere,et al. HLA-DR-restricted peptides identified in the Nef protein can induce HIV type 1-specific IL-2/IFN-gamma-secreting CD4+ and CD4+ /CD8+ T cells in humans after lipopeptide vaccination. , 2007, AIDS research and human retroviruses.
[122] Tin Wee Tan,et al. In silico characterization of immunogenic epitopes presented by HLA-Cw*0401 , 2007, Immunome research.
[123] J. Banga,et al. Application of HLA class II transgenic mice to study autoimmune regulation. , 2007, Thyroid : official journal of the American Thyroid Association.
[124] Leonard Moise,et al. Prediction of immunogenicity for therapeutic proteins: state of the art. , 2007, Current opinion in drug discovery & development.
[125] K. Hirata,et al. Efficient Cross-Presentation by Heat Shock Protein 90-Peptide Complex-Loaded Dendritic Cells via an Endosomal Pathway , 2007, The Journal of Immunology.
[126] R. Kennedy,et al. T‐Cell epitope discovery for variola and vaccinia viruses , 2007, Reviews in medical virology.
[127] R. Tampé,et al. Identification of a Lysosomal Peptide Transport System Induced during Dendritic Cell Development* , 2007, Journal of Biological Chemistry.
[128] R. Rappuoli,et al. The pan-genome: towards a knowledge-based discovery of novel targets for vaccines and antibacterials. , 2007, Drug discovery today.
[129] David Heckerman,et al. Leveraging Information Across HLA Alleles/Supertypes Improves Epitope Prediction , 2007, J. Comput. Biol..
[130] Lei Huang,et al. A probabilistic meta-predictor for the MHC class II binding peptides , 2007, Immunogenetics.
[131] T. Reinheckel,et al. A Transporter Associated with Antigen-Processing Independent Vacuolar Pathway for the MHC Class I-Mediated Presentation of Endogenous Transmembrane Proteins , 2007, The Journal of Immunology.
[132] James McCluskey,et al. More than one reason to rethink the use of peptides in vaccine design , 2007, Nature Reviews Drug Discovery.
[133] L. Stern,et al. Human CD4+ T Cell Epitopes from Vaccinia Virus Induced by Vaccination or Infection , 2007, PLoS pathogens.
[134] Matthew N Davies,et al. Harnessing bioinformatics to discover new vaccines. , 2007, Drug discovery today.
[135] Gajendra P.S. Raghava,et al. A hybrid approach for predicting promiscuous MHC class I restricted T cell epitopes , 2007, Journal of Biosciences.
[136] Rainer Blasczyk,et al. Implementing the modular MHC model for predicting peptide binding. , 2007, Methods in molecular biology.
[137] Tomer Hertz,et al. Identifying HLA supertypes by learning distance functions , 2007, Bioinform..
[138] C. Akdis,et al. Targeting the MHC II presentation pathway in allergy vaccine development. , 2007, Biochemical Society transactions.
[139] Claude Auriault,et al. Determination of a HLA II Promiscuous Peptide Cocktail as Potential Vaccine Against EBV Latency II Malignancies , 2007, Journal of immunotherapy.
[140] G. Parmiani,et al. Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials1 , 2007, The Journal of Immunology.
[141] R. Naz,et al. Peptide vaccines against cancer, infectious diseases, and conception. , 2007, Frontiers in bioscience : a journal and virtual library.
[142] Zhao-You Tang,et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[143] Morten Nielsen,et al. Modeling the adaptive immune system: predictions and simulations , 2007, Bioinform..
[144] Tin Wee Tan,et al. Evolutionarily Conserved Protein Sequences of Influenza A Viruses, Avian and Human, as Vaccine Targets , 2007, PloS one.
[145] Morten Nielsen,et al. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method , 2007, BMC Bioinformatics.
[146] P. Sabbatini,et al. Immunologic approaches to ovarian cancer treatment. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[147] Tin Wee Tan,et al. Methods and protocols for prediction of immunogenic epitopes , 2006, Briefings Bioinform..
[148] Tin Wee Tan,et al. Conservation and Variability of Dengue Virus Proteins: Implications for Vaccine Design , 2008, PLoS neglected tropical diseases.
[149] Uthaman Gowthaman,et al. In silico tools for predicting peptides binding to HLA-class II molecules: more confusion than conclusion. , 2008, Journal of proteome research.
[150] Morten Nielsen,et al. Quantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpan , 2008, PLoS Comput. Biol..
[151] E. Tartour,et al. Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients1 , 2008, The Journal of Immunology.
[152] John Sidney,et al. A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach , 2008, PLoS Comput. Biol..
[153] 黒瀧 武洋. Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway , 2008 .
[154] Clemencia Pinilla,et al. Thyroglobulin Peptides Associate In Vivo to HLA-DR in Autoimmune Thyroid Glands1 , 2008, The Journal of Immunology.
[155] Bjoern Peters,et al. Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries , 2008, Immunome research.
[156] S. Lee,et al. HLA A 2 . 1-Restricted Cytotoxic T Cells Recognizing a Range of Epstein-Barr Virus Isolates through a Defined Epitope in Latent Membrane Protein LMP 2 , 2022 .